LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Lineage Cell Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$0.95−0.03 (-2.61%)
Close on Oct 19, 2026
- Market cap
- $249.13M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
46.1%
117M of 253M shares
Institutional holders
131
35 new, 32 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
1 buys · 0 sales
Net bought $24.45K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Neal C. Bradsher | 57,848,357 | 23.10% | 13D (active) amendment | Nov 12, 2025 |
| BlackRock, Inc. | 13,185,489 | 5.30% | 13G (passive) | Jun 30, 2026 |
| Chernett Jorey | 11,445,003 | 5.00% | 13G (passive) | Sep 22, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of LCTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Broadwood Capital Inc | 49,560,992 | 19.60% | $64.92M | – | 3.39% |
| BlackRock, Inc. | 13,186,895 | 5.21% | $17.27M | +9,322,138 | 0.00% |
| Vanguard Capital Management LLC | 9,054,918 | 3.58% | $11.86M | +736,233 | 0.00% |
| Defender Capital, LLC. | 6,598,899 | 2.61% | $8.64M | −130,700 | 2.81% |
| Geode Capital Management, LLC | 5,299,457 | 2.10% | $6.94M | +2,776,343 | 0.00% |
| Raffles Associates LP | 5,197,788 | 2.06% | $6.81M | −165,000 | 2.99% |
| Fifth Third Bancorp | 4,600,000 | 1.82% | $6.03M | – | 0.01% |
| Millennium Management LLC | 3,018,567 | 1.19% | $3.95M | −2,542,807 | 0.00% |
| State Street Corp | 2,314,180 | 0.92% | $3.03M | +1,224,069 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,668,629 | 0.66% | $2.19M | +344,471 | 0.00% |
| Northern Trust Corp | 1,656,651 | 0.66% | $2.17M | +1,157,524 | 0.00% |
| Morgan Stanley | 1,471,462 | 0.58% | $1.93M | −397,029 | 0.00% |
| Renaissance Technologies LLC | 1,344,829 | 0.53% | $1.76M | −780,271 | 0.00% |
| Marshall Wace, Llp | 1,282,347 | 0.51% | $1.68M | −1,782,686 | 0.00% |
| Vanguard Portfolio Management LLC | 1,273,311 | 0.50% | $1.67M | New | 0.00% |
| UBS Group AG | 687,051 | 0.27% | $900.04K | −683,410 | 0.00% |
| Red Crane Wealth Management, LLC | 597,263 | 0.24% | $782.42K | – | 0.58% |
| Charles Schwab Investment Management Inc | 577,435 | 0.23% | $756.44K | +447,511 | 0.00% |
| Barclays PLC | 508,668 | 0.20% | $666.35K | +115,359 | 0.00% |
| Squarepoint Ops LLC | 444,774 | 0.18% | $582.65K | +301,584 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 131 | 117M | 46.1% | 35 / 25 | 30 / 32 | 21M | 16M |
| Q1 2026 | 130 | 112M | 44.2% | 24 / 37 | 26 / 12 | 27M | 2M |
| Q4 2025 | 123 | 102M | 40.2% | 25 / 30 | 28 / 12 | 18M | 4M |
| Q3 2025 | 112 | 88M | 34.8% | 17 / 23 | 33 / 34 | 3M | 13M |
| Q2 2025 | 129 | 98M | 38.8% | 35 / 23 | 35 / 32 | 11M | 22M |
| Q1 2025 | 127 | 109M | 43.3% | 19 / 38 | 22 / 16 | 17M | 15M |
| Q4 2024 | 126 | 107M | 42.4% | 28 / 37 | 17 / 13 | 21M | 9M |
| Q3 2024 | 114 | 95M | 37.7% | 9 / 28 | 25 / 7 | 12M | 7M |
| Q2 2024 | 113 | 100M | 39.4% | 8 / 35 | 26 / 11 | 8M | 4M |
| Q1 2024 | 116 | 95M | 37.6% | 15 / 30 | 31 / 12 | 20M | 2M |
| Q4 2023 | 115 | 77M | 30.4% | 15 / 27 | 25 / 4 | 4M | 2M |
| Q3 2023 | 104 | 76M | 29.9% | 6 / 26 | 24 / 9 | 3M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of LCTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 5,907,404 | 2.34% | $7.74M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 4,159,208 | 1.64% | $5.45M | 0.01% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 2,962,901 | 1.17% | $3.88M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,994,857 | 0.79% | $2.15M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 1,730,644 | 0.68% | $2.27M | 0.01% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,322,034 | 0.52% | $1.73M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 1,196,937 | 0.47% | $1.59M | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 617,154 | 0.24% | $808.47K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 447,526 | 0.18% | $483.33K | 0.01% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 438,359 | 0.17% | $583.02K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 346,304 | 0.14% | $460.58K | 0.00% | May 31, 2026 |
| Master Small Cap Index Series | 344,484 | 0.14% | $451.27K | 0.01% | Jun 30, 2026 |
| Nuveen Small Cap Blend Index Fund | 245,384 | 0.10% | $265.01K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 221,000 | 0.09% | $289.51K | 0.20% | Jun 30, 2026 |
| EQ/2000 Managed Volatility Portfolio | 193,554 | 0.08% | $253.56K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Brian M. Culley | President and CEO, Director | 255,516 | 0.10% | Mar 12, 2026 |
| Jill Ann Howe | Chief Financial Officer | 25,500 | 0.01% | Mar 6, 2026 |
| George A. Samuel III | General Counsel and Secretary | 31,063 | 0.01% | Mar 6, 2026 |
| Anula Jayasuriya | Director | 10,000 | 0.00% | Jul 2, 2026 |
| Dipti Amin | Director | 35,000 | 0.01% | Jul 2, 2026 |
| Deborah J. Andrews | Director | 34,720 | 0.01% | Jul 2, 2026 |
| Angus C. Russell | Director | 92,220 | 0.04% | Jul 2, 2026 |
| Neal C. Bradsher | Director, 10% owner | 104,136,455 | 41.18% | Jul 2, 2026 |
| Michael H. Mulroy | Director | 298,555 | 0.12% | Jul 2, 2026 |
| Broadwood Partners, L.P. | Director, 10% owner | 83,332,510 | 32.95% | Jan 28, 2025 |
| Capital Inc Broadwood | 10% owner | 99,121,984 | 39.19% | Jan 28, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Brian M. Culley President and CEO, Director | Mar 12, 2026 | Buy | +15,000 | $1.63 | $24.45K | 255,516 |
| George A. Samuel III General Counsel and Secretary | Feb 11, 2026 | Tax withholding | −2,502 | $1.80 | $4.50K | 31,063 |
| George A. Samuel III General Counsel and Secretary | Feb 11, 2026 | Option exercise | +6,075 | – | – | 33,565 |
| Brian M. Culley President and CEO, Director | Feb 11, 2026 | Tax withholding | −12,869 | $1.80 | $23.16K | 240,516 |
| Brian M. Culley President and CEO, Director | Feb 11, 2026 | Option exercise | +31,250 | – | – | 253,385 |
| George A. Samuel III General Counsel and Secretary | Dec 19, 2025 | Tax withholding | −65 | $1.68 | $109 | 27,490 |
| George A. Samuel III General Counsel and Secretary | Dec 19, 2025 | Award | +1,735 | – | – | 27,555 |
| Brian M. Culley President and CEO, Director | Dec 19, 2025 | Tax withholding | −334 | $1.68 | $561 | 222,135 |
| Brian M. Culley President and CEO, Director | Dec 19, 2025 | Award | +8,925 | – | – | 222,469 |
| George A. Samuel III General Counsel | Feb 11, 2025 | Tax withholding | −2,440 | $0.65 | $1.59K | 25,820 |
| George A. Samuel III General Counsel | Feb 11, 2025 | Option exercise | +6,076 | – | – | 28,260 |
| Brian M. Culley President and CEO, Director | Feb 11, 2025 | Tax withholding | −12,547 | $0.65 | $8.16K | 213,544 |
| Brian M. Culley President and CEO, Director | Feb 11, 2025 | Option exercise | +31,249 | – | – | 226,091 |
| Capital Inc Broadwood 10% owner | Jan 27, 2025 | Buy | +0 | – | – | 49,560,992 |
| Capital Inc Broadwood 10% owner | Jan 27, 2025 | Buy | +7,894,737 | $0.76 | $6.00M | 49,560,992 |
| Jill Ann Howe Chief Financial Officer | Nov 26, 2024 | Buy | +15,000 | $0.59 | $8.85K | 25,500 |
| George A. Samuel III General Counsel | Nov 26, 2024 | Buy | +15,000 | $0.60 | $9.00K | 22,184 |
| Michael H. Mulroy Director | Nov 22, 2024 | Buy | +40,000 | $0.57 | $22.80K | 298,555 |
| Brian M. Culley President and CEO, Director | Nov 21, 2024 | Buy | +40,000 | $0.60 | $24.00K | 194,842 |
| Jill Ann Howe Chief Financial Officer | Aug 16, 2024 | Buy | +10,500 | $0.89 | $9.35K | 10,500 |
| Brian M. Culley President and CEO, Director | May 24, 2024 | Buy | +10,000 | $1.05 | $10.50K | 154,842 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2024 | Tax withholding | −2,490 | $1.08 | $2.69K | 7,184 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2024 | Option exercise | +6,076 | – | – | 9,674 |
| Brian M. Culley President and CEO, Director | Feb 11, 2024 | Tax withholding | −12,806 | $1.08 | $13.83K | 144,842 |
| Brian M. Culley President and CEO, Director | Feb 11, 2024 | Option exercise | +31,249 | – | – | 157,648 |
| Don M. Bailey Director | Feb 8, 2024 | Buy | +96,155 | $1.04 | $100.00K | 158,801 |
| Broadwood Partners, L.P. Director, 10% owner | Feb 6, 2024 | Buy | +6,730,770 | $1.04 | $7.00M | 41,666,255 |
| Broadwood Partners, L.P. Director, 10% owner | Feb 6, 2024 | Buy | +0 | – | – | 41,666,255 |
| Anula Jayasuriya Director | Dec 29, 2023 | Buy | +10,000 | $1.09 | $10.90K | 10,000 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Feb 11, 2023 | Tax withholding | −5,310 | $1.35 | $7.17K | 7,710 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Feb 11, 2023 | Option exercise | +13,020 | – | – | 13,020 |
| Brian M. Culley President and CEO, Director | Feb 11, 2023 | Tax withholding | −12,744 | $1.35 | $17.20K | 126,399 |
| Brian M. Culley President and CEO, Director | Feb 11, 2023 | Option exercise | +31,249 | – | – | 139,143 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2023 | Tax withholding | −2,478 | $1.35 | $3.35K | 3,598 |
| George A. Samuel III General Counsel/Secretary | Feb 11, 2023 | Option exercise | +6,076 | – | – | 6,076 |
| Alfred D. Kingsley Director | Dec 1, 2022 | Gift | −25,000 | – | – | 5,430,545 |
| Brian M. Culley President and CEO, Director | Jun 30, 2022 | Tax withholding | −5,343 | $1.58 | $8.44K | 107,894 |
| Brian M. Culley President and CEO, Director | Jun 30, 2022 | Option exercise | +15,450 | – | – | 113,237 |
| Brian M. Culley President and CEO, Director | Mar 31, 2022 | Option exercise | +15,450 | – | – | 96,730 |
| Brian M. Culley President and CEO, Director | Mar 31, 2022 | Tax withholding | −5,343 | $1.54 | $8.23K | 91,387 |
| Brian M. Culley President and CEO, Director | Mar 31, 2022 | Buy | +6,400 | $1.53 | $9.79K | 97,787 |
| Dipti Amin Director | Mar 28, 2022 | Buy | +35,000 | $1.63 | $57.05K | 35,000 |
| Brian M. Culley President and CEO, Director | Mar 25, 2022 | Buy | +5,250 | $1.38 | $7.24K | 81,280 |
| Neal C. Bradsher Director, 10% owner | Mar 25, 2022 | Buy | +0 | – | – | 34,935,485 |
| Neal C. Bradsher Director, 10% owner | Mar 25, 2022 | Buy | +470,000 | $1.44 | $676.80K | 34,935,485 |
| Neal C. Bradsher Director, 10% owner | Mar 24, 2022 | Buy | +0 | – | – | 34,465,485 |
| Neal C. Bradsher Director, 10% owner | Mar 24, 2022 | Buy | +200,000 | $1.42 | $284.00K | 34,465,485 |
| Michael H. Mulroy Director | Mar 24, 2022 | Buy | +7,000 | $1.40 | $9.80K | 258,555 |
| Neal C. Bradsher Director, 10% owner | Mar 23, 2022 | Buy | +260,106 | $1.37 | $356.35K | 34,265,485 |
| Neal C. Bradsher Director, 10% owner | Mar 23, 2022 | Buy | +0 | – | – | 34,265,485 |
| Brian M. Culley President and CEO, Director | Dec 31, 2021 | Tax withholding | −5,343 | $2.45 | $13.09K | 76,030 |
| Brian M. Culley President and CEO, Director | Dec 31, 2021 | Option exercise | +15,450 | – | – | 81,373 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 29, 2021 | Sale | −28,445 | $2.44 | $69.41K | 0 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 29, 2021 | Sale | −9,250 | $2.49 | $23.03K | 28,445 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 29, 2021 | Option exercise | +9,250 | $0.69 | $6.38K | 37,695 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Sale | −501,588 | $2.45 | $1.23M | 28,445 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Option exercise | +79,689 | $1.14 | $90.85K | 530,033 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Option exercise | +236,899 | $2.11 | $499.86K | 450,344 |
| Gary S. Hogge SVP,Clinical & Medical Affairs | Dec 28, 2021 | Option exercise | +185,000 | $0.69 | $127.65K | 213,445 |
| Alfred D. Kingsley Director | Dec 1, 2021 | Gift | −14,700 | – | – | 5,455,545 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| M. Bailey Don Director | Sep 24, 2025 | 60,000 | $96.02K | Sep 24, 2025 | Stock Option Exercise |
| M. Bailey Don Director | Sep 10, 2025 | 80,000 | $97.47K | Sep 10, 2025 | Stock Option Exercise |